Patient Compliance With Outpatient Prophylaxis: An Observational Study
|
|
- Abraham Pitts
- 7 years ago
- Views:
Transcription
1 Patient Compliance With Outpatient Prophylaxis: An Observational Study CLIFFORD W. COLWELL, JR, MD*; PAMELA PULIDO, BSN, RN*; MARY E. HARDWICK, MSN, RN*; BEVERLY A. MORRIS, RN, CNP abstract The need for prophylaxis against venous thromboembolic disease following lower-extremity joint replacement is well documented and accepted. Although low molecular weight heparin is approved for inpatient and extended prophylaxis beyond the hospital environment, orthopedic surgeons must determine the duration of injectable low molecular weight heparin based on the period of venous thromboembolic disease risk and on patient compliance with self-administration of medication at home. Lack of confidence in patients ability to self-administer injections may contribute to hesitancy in prescribing injectable prophylaxis. This observational study evaluated the effectiveness of a self-injection education program. Findings demonstrate that when properly instructed, patients safely and efficaciously self-administer low molecular weight heparin at home. With shorter hospital stays, self-administration of low molecular weight heparin may optimize the clinical outcomes of orthopedic patients. Antithrombotic prophylaxis for the prevention of venous thromboembolic disease following total joint arthroplasty is recommended. Without the use of prophylaxis, thromboembolic complications have been reported in 50% to 80% of patients screened with venography after surgery. 1,2 In contrast, the incidence of clinically symptomatic thromboembolic complications after early prophylaxis of 7 to 10 days has been estimated to be 5%. 3,4 Since 1986, it has been recommended patients undergoing total joint arthroplasty receive prophylaxis for the prevention of venous thromboembolic disease for a minimum of 7 to 10 days. 5 In 1993, a low molecular weight heparin, Lovenox (enoxaparin sodium; Aventis Pharmaceuticals Inc, Bridgewater, NJ), was approved for prophylactic use following total hip replacement, and in 1995, Lovenox received approval for prophylactic use following total knee arthroplasty. Since then, its use has become widespread, and as early as the 1995 ACCP Conference, 7 to 10 days of enoxaparin was recommended as an A1 method of prophylaxis for the prevention of thromboembolism. 6 A study of extended use of enoxaparin 40 mg once a day for an additional 14 days, based on an initial 7 to 10 days of enoxaparin (30 mg every 12 hours), demonstrated the relative risk of thrombosis was reduced by 42% compared with placebo, thereby establishing the efficacy of extended use. 7 In 1998, extended use was approved by the US Food and Drug Administration. 8 With the current hospital stay averaging 4 days, this extended use of enoxaparin has necessitated that patients self-administer injections at home to obtain the benefits of the 7- to 10-day prophylaxis regimen. Orthopedic surgeons face the dilemma of determining the duration of low molecular weight heparin administration based on the period of risk and patients compliance with self-medication after hospital discharge to their home. However, orthopedic surgeons lack of confidence in patients ability to self-administer injections may contribute to hesitancy in prescribing this type of prophylaxis. The lack of confidence in patient compliance is not unfounded. Overall oral medication compliance rates have been reported to range from 10% to 94%. 9 Greenberg 10 reported once-daily and twice-daily medication regimens were associated with significantly better compliance (73% and 70%, respectively) than medication regimens of three times daily (52%) and four times daily (42%). 10 Sackett and Snow 11 found short-term medication treatment had a better compliance From the *Scripps Clinic, La Jolla, Calif, and DePuy Johnson & Johnson, Warsaw, Ind. Reprint requests: Clifford W. Colwell, Jr, MD, Scripps Clinic, N Torrey Pines Rd, MS126, La Jolla, CA FEBRUARY 2005 Volume 28 Number 2 143
2 TABLE 1 Patient Enrollment and Exclusion in the Enoxaparin Self-Injection Study No. Patients screened 70 Patients enrolled 62 Patients excluded prior to study 11 Discharged to skilled nursing facility 5 Surgery cancelled 2 Use of routine anticoagulant 1 Retinal hemorrhage 1 Consent withdrawn 2 Total study participants 51 Patients discontinuing during study 11 Hospital readmission 4 Inability to follow instructions 2 Gastrointestinal bleeding 1 Incision swelling 1 Inconvenience 3 Total completing study (returned diary cards) 40 rate (78%) than long-term treatment (53%). Moreover, an estimated 50% to 90% of patients make unintentional errors when taking medications. 10 The predominant type of noncompliance is dose omissions. 12 Patient compliance with shortterm use of an injectable medication is unknown as a literature search yielded no references on this topic. Patient compliance in home care is a major health issue, with outcomes related to levels of morbidity, mortality, and cost utilization. The most promising strategy to enhance compliance is a combination of interventions including patient education, contracts, self-monitoring, social support, telephone follow-up, and individualized treatment. 13 The majority of patient compliance research focuses on efforts to raise individual compliance; few studies have compliance as the outcome. This study was designed primarily to evaluate individual patients ability to both comply with self-injection and change the dosage and frequency of a regimen during the prescribed treatment period. A secondary goal was to evaluate the effectiveness of a routine self-injection education program to increase orthopedic surgeons confidence in patients ability to self-administer injections. MATERIALS AND METHODS Population Patients who were scheduled for primary or revision elective total hip and knee arthroplasty were prospectively and sequentially recruited into the study. Patients who were willing to participate in therapy and phone interviews for 21 days after surgery gave written consent. Patients with mental or physical limitations to selfadminister injections or planned discharge to other care facilities were excluded. Therapy consisted of postoperative antithrombotic prophylaxis using subcutaneous enoxaparin to prevent venous thromboembolic complications. Patients enrolled in the study agreed to complete the therapy of enoxaparin, participate in 3 follow-up phone interviews with an independent pharmacist, complete self-report injection diaries, and return the diaries to the agency collecting the data. Study Design This observational open-label investigation was conducted at Scripps Clinic in La Jolla, California, using routine enoxaparin patient education. The study was approved by the institutional review board. At a preoperative education class, a clinical nurse discussed enoxaparin, the rationale for its use, and the method of administration. Treatment with 30 mg of enoxaparin every 12 hours began in the hospital on the first postoperative day and continued throughout the hospital stay. Hospital staff nurses began the selfinjection education process with the first injection and continued patient education throughout patients hospital stay. As part of the education, a staff nurse explained the purpose of low molecular weight heparin therapy, demonstrated the subcutaneous injection, and discussed the patient s responsibilities following discharge from the hospital. After instruction, with a staff nurse observing, patients (or a family member designated to administer the injections), demonstrated their injection technique. At that time, the nurse reviewed dosage and regimen schedules with the patients. Patients also were given a take-home selfinjection kit that included an instructional video developed by the manufacturer and written instructional materials outlining the subcutaneous injection technique and potential side effects. On discharge from the hospital, the study coordinator provided a complete supply of syringes prefilled with enoxaparin. Written instructions indicated 30 mg of enoxaparin were to be administered subcutaneously at 9:00 AM and 9:00 PM from postoperative days 1 to 7 and then 40 mg were to be administered subcutaneously at 9:00 AM daily from postoperative days 8 to 21. This regimen followed the same 21-day protocol outlined in a previous study, which reported a 41% risk reduction of thrombosis compared with placebo after 7 to 10 days of treatment. 7 Patients also were given diary cards to complete regarding injection compliance. Demographics and a checklist assessing the education received were obtained from the patients at discharge and were sent to trained pharmacists for independent third-party data collection. Measurement of Compliance Compliance was measured by indirect detection methods consisting of phone interviews by an independent pharmacist and completion of subjective diaries by each participant. Calls were placed on 3 separate occasions (days 5, 13, and 21), throughout the 21-day enoxaparin therapy, with a consistent script read to patients at each call. The pharmacist documented the answers to the questions in the script. Data from the phone interviews and patient diaries were used to determine outcomes. Only returned patient diary cards were used to determine complete or partial compliance. Assessment of enoxaparin usage infor- 144 ORTHOPEDICS
3 PATIENT COMPLIANCE COLWELL ET AL TABLE 2 Patient Demographics of Enoxaparin Self-Injection Study (N=51) Demographic No. (%) Gender Women 27 (53) Men 24 (47) Joint Hip 30 (59) Knee 21 (41) Type of surgery Primary 45 (88) Revision 6 (12) Ethnicity White 49 (96) Hispanic 2 (4) Body mass index Mean Women 26.6 Men 26.7 Age (years) Mean 68.4 Range Length of hospital stay (days) Mean 3.4 Range 2-5 mation received by patients prior to hospital discharge for home therapy was ascertained by a discharge questionnaire and questions to patients during the first phone call. Instruction on completion of the diary cards also was reviewed with patients during the first phone call. The second phone call assessed the success of the change in dosage from 30 mg every 12 hours to 40 mg once daily. Finally, the third call gathered a global assessment of the medication therapy and concluded with a reminder to return the diary cards by mail. RESULTS Of 70 patients screened to participate, a total of 62 patients were prospectively enrolled in the study. Of these, 11 patients were excluded: 5 patients were discharged to a skilled nursing facility, 2 patients cancelled their surgery, 1 was discovered to use routine anticoagulants, 1 had a retinal hemorrhage before surgery, and 2 withdrew their consent. This left 51 patients TABLE 3 Patient Compliance in the Enoxaparin Self-Injection Study Based on Returned Diary Cards (N=51) No. (%) Assessable for compliance 40 (78.4) Overall compliance (partial and complete) 37 (92.5) Complete compliance* 22 (55) Partial compliance 15 (37.5) Noncompliance 3 (7.5) *Defined as 7 days of 30 mg every 12 hours followed by 14 days of 40 mg once daily with all doses given within 1 hour of scheduled administration time. Defined as at least 6 days of 30 mg every 12 hours followed by at least 13 days of 40 mg once a day, and all doses given within 2 hours. Defined as <6 days of 30 mg every 12 hours or <13 days of 40 mg once a day. participating in the study (Table 1). Twenty-seven (53%) patients were women and 24 (47%) patients were men. Mean patient age was 68 years (range: years). Thirty (59%) patients underwent hip arthroplasty and 21 (41%) underwent knee arthroplasty. Forty-five (88%) were primary arthroplasties and 6 (12%) were revision arthroplasties. Mean length of hospital stay was 3.4 days (range: 2-5 days) (Table 2). Of the 51 patients enrolled, 7 (14%) reported a family member or friend gave them the injections. Forty (78%) patients reported completing both enoxaparin regimens by returning diary cards. Eleven patients discontinued study participation during the 40-mg once-daily regimen (Table 1). Four of the 11 patients were readmitted to the hospital before completion. Two of these patients were readmitted for hip dislocation and underwent surgical cup revision; neither patient experienced any unusual bleeding at the surgical site. One patient experienced a dislocation and underwent a closed reduction with incision and drainage of a wound hematoma. One patient was admitted for a partial bowel obstruction, which resolved. Of the remaining seven patients who discontinued study participation, one patient was withdrawn by the physician due to swelling unrelated to bleeding at the incision site. One patient with a history of colitis discontinued the enoxaparin 40 mg after 11 doses because of the presence of blood in the stools. Two patients were discontinued by their physicians after each patient took 40 mg every 12 hours for 6 days without any adverse events. Three patients withdrew from the study citing inconvenience of medication. Compliance Forty (78%) of 51 patients were considered evaluable based on the completion of the medication regimen and the return of completed diary cards. Of these 40 evaluable patients, a total of 37 (92%) were compliant, including partial and complete compliance. Complete compliance, defined as 7 days of 30 mg every 12 hours, followed by a regimen of 40 mg once daily for 14 days, with all doses given within 1 hour of the scheduled administration time, was achieved by 22 (55%) patients. Partial compliance, defined as at least 6 days of 30 mg every 12 hours, followed by at least 13 days of 40 mg once daily, with all doses given within 2 hours of scheduled administration time, was achieved by 15 (37%) patients. The remaining 3 (7%) patients were considered noncompliant, which was defined as 6 days of 30 mg twice daily or 13 days of 40 mg once daily (Table 3). Two of the noncompliant patients were unable to follow instructions and used 40 mg of enoxaparin every 12 hours after discharge; one patient stated she did not receive the 30-mg syringes at discharge, and the second patient did not understand the instructions, although written direc- FEBRUARY 2005 Volume 28 Number 2 145
4 TABLE 4 Patient Education Program Assessment for the Enoxaparin Self-Injection Study (N=50)* No. (%) Received a complimentary 50 (100) enoxaparin injection kit Watched the video about 14 (28) enoxaparin Understood why it was 49 (98) important to self-administer enoxaparin injections Taught how and where to 49 (98) give self-injections Practiced giving self- 35 (70) injections with a healthcare professional observing Comfortable giving self- 34 (68) injections Knew when to give 50 (100) 30-mg dose Knew when to give 49 (98) 40-mg dose *Checklist not received from one patient. tions were sent home with both patients. Neither of these patients experienced any bleeding or adverse events. Outcomes Safety issues involved one patient with a history of colitis with blood in the stools at day 11 of treatment that cleared within 2 days after discontinuation of enoxaparin and one patient with a wound hematoma after dislocation and closed reduction. Sixteen patients reported burning or stinging at the injection site, and one patient reported bruising at the injection site. All of these adverse events were reported as mild. None of the patients experienced any clinical thromboembolic events. At the end of the routine education program provided by the hospital nurses, completed checklists were received from 50 of the 51 evaluable patients. Of these 50 patients, 49 (98%) reported understanding why it was important to self-administer enoxaparin, and were taught how and where to administer the injections. Only 14 (28%) patients reported viewing the video that was provided. Thirty-five (70%) TABLE 5 Subjective Patient Information for the Enoxaparin Self-Injection Study (N=51) Question No. Mean Range During Week 2 of Therapy How are you doing on your enoxaparin medication? (1=poor, 10=excellent) During Week 3 of Therapy How are you doing on your enoxaparin medication? (1=poor, 10=excellent) Do you feel you received enough information on how to give your medication? (1=no information, Do you feel you received enough information on when to give your medication? (1=no information, Was the syringe easy for you to use? (1=very easy, =very difficult) After Completion of Therapy Do you feel you received the proper information on how to give your medication? (1=no information, Do you feel you received enough information on when to give your medication? (1=no information, Was the syringe easy for you to use? (1=very difficult, =very easy) patients reported practicing self-injections with a staff nurse observing, and 38 (76%) said they were comfortable giving the selfinjections. At hospital discharge, 100% of the patients reported knowing when to administer enoxaparin 30 mg, and 49 (98%) reported knowing when to administer the 40-mg injections (Table 4). At the end of the first week of therapy, all patients stated they understood the medication information provided at discharge and knew the reason for using the medication. Twenty-one (42%) of 50 reported they reviewed the discharge information. During the follow-up phone calls, patients were asked to describe their perception of certain aspects of therapy using a 10-point scale (Table 5). Regarding how well patients perceived they were doing with the enoxaparin injections, with 1 being poor and 10 being excellent, the mean response was 8.7 for 48 patients during the second week and 8.9 for 43 patients during the third week. During the third-week interview, regarding whether patients had patients received enough information on how to administer their medication, the mean response was 9.2 (1=no information and. Regarding whether they had received enough information on when to administer their medication, the mean response was 9.4 (1=no information and. Regarding whether the syringe was easy to use, the mean response was 2.3 (1=very easy and 10=very difficult) (Table 5) After the completion of therapy, 36 patients again responded in a returned questionnaire using a scale of 1 to 10 (1=no information and, as to whether they had received enough information on how (mean: 8.8, range: 1-10) and when (mean: 8.9, range: 1-10) to administer the medication. The mean response as to whether the syringe was easy to use was 8.8 (range: 1-10, with 1=very difficult and 10=very easy). Of the 42 patients who returned the final questionnaire, 100% stated they received an explanation of why the medication was necessary and instructions on 146 ORTHOPEDICS
5 PATIENT COMPLIANCE COLWELL ET AL how to administer the medication. Forty (95%) reported they felt they could administer the self-injection at discharge. DISCUSSION Developing a supportive, nonjudgmental, and positive relationship with patients serves to motivate them to comply with a prescribed regimen. 14 A regimen that is simple and easy to follow also facilitates compliance. 15 According to Wixted et al, 16 routine assessment of clinical outcomes with regular feedback allows surgeons to objectively monitor their practice patterns and has the potential to improve patient care. The goal of this study was to assess patient compliance with a prophylactic medication protocol that included a change of both dose and administration times. By phone interview, 50 (98%) of 51 reported completing the initial therapy, but only 41 (80%) of 51 reported completing the second part of therapy. Overall compliance rate, including complete and partial compliance, was 92%, indicating patients can complete the prophylactic therapy. A second goal of the study was to assess the education patients received about the medication and self-injection. Ninety-eight percent of the patients reported knowing the reason for selfadministration of enoxaparin and when to administer the 40-mg dose. Forty-two percent reviewed the information at home after discharge, indicating the value of providing information in written and video formats. These findings and the overall compliance rate indicate the education program provided by the nursing staff was successful at explaining the reason for therapy and providing information in a format patients understood. The only difference between the study patient cohort and the normal patient cohort was the follow-up conducted by telephone. This study cannot document compliance would be the same if there were no follow-up; however, compliance could not be evaluated without some type of followup. Although this study is relatively small with both phone calls and diaries for evaluation of compliance, it is compatible with other studies of compliance. This study does not imply that every patient cohort will respond with similar numbers or what the numbers would be if there were no follow-up. With earlier and earlier discharge from the hospital and increasing recommendations for care outside of the hospital, by necessity, patients will need to take more responsibility for all types of medications following discharge. This study links two different doses and dosing schedules with drug compliance following hospital discharge. When appropriately instructed and monitored, many patients can safely and efficaciously self-administer enoxaparin in the home setting, optimizing the benefits of this medical intervention and the goal of decreasing thromboembolic complications following total joint arthroplasty. REFERENCES 1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001; 119 (suppl):132s-175s. 2. Lotke PA, Ecker ML, Alavi A, Berkowitz H. Indications for the treatment of deep venous thrombosis following total knee replacement. J Bone Joint Surg Am. 1984; 66: Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996; 348: Colwell CW Jr, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop. 1995; 319: Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA. 1986; 256: Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest. 1995; 108(suppl):312S-334S. 7. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001; 83: Physicians Desk Reference. Montvale, NJ: Medical Economics, Simons MR. Interventions related to compliance. Nurs Clin North Am. 1992; 27: Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984; 6: Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, Md: The Johns Hopkins University Press; 1979: Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997; 20: Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation. 1997; 95: Currie BF, Renner JH. Patient education. Developing a health care partnership. Postgrad Med. 1975; 65: , Padrick KP. Compliance: myth and motivators. Top Clin Nurs. 1986; 5: Wixted JJ, Grover NK, Anderson FA Jr, Fitzgerald RH Jr. Clinical outcomes in orthopaedic surgery. The collaborative efforts of orthopaedic surgeons with industry. Bull Hosp Jt Dis. 1999; 58: FEBRUARY 2005 Volume 28 Number 2 147
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery Position Statement There is currently insufficient data for the (AOFAS) to recommend for or against routine VTED prophylaxis for
More informationRandomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationPrior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
More informationXARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery
XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)
More informationDATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
More informationOverview of the TJC/CMS VTE Core Measures
Overview of the TJC/CMS VTE Core Measures CMS Specification Manual 4.2 January 1, 2013 June 30, 2013 Victoria Agramonte, RN, MSN Project Manager, IPRO VTE Regional Learning Sessions NYS Partnership for
More informationInvestor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationNational Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Goal 1 Nursing are enter ccreditation Program Improve the accuracy of patient and resident identification. NPSG.01.01.01 Use at least two patient or resident identifiers when
More informationBackgrounder. Current anticoagulant therapies
Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationValue-Based Purchasing
Emerging Topics in Healthcare Reform Value-Based Purchasing Janssen Pharmaceuticals, Inc. Value-Based Purchasing The Patient Protection and Affordable Care Act (ACA) established the Hospital Value-Based
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 March 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 ARIXTRA 1.5 mg/0.3 ml, solution for injection in pre-filled syringe Box of 2 (CIP: 363 500-6) Box of
More informationNational Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Effective January 1, 2015 Goal 1 Improve the accuracy of resident identification. NPSG.01.01.01 Long Term are ccreditation Program Medicare/Medicaid ertification-based Option
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationEnhanced recovery programme after TKA through multi-disciplinary collaboration
Enhanced recovery programme after TKA through multi-disciplinary collaboration ChanPK(1), ChiuKY(1), FungYK(6), YeungSS(7), NgT(8), ChanMT(5), LamR(4), WongNY(3), ChoiYY(3), ChanCW(2), NgFY(1), YanCH(1)
More information2. Background This indication of rivaroxaban had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the
More informationSummary and general discussion
Chapter 7 Summary and general discussion Summary and general discussion In this thesis, treatment of vitamin K antagonist-associated bleed with prothrombin complex concentrate was addressed. In this we
More informationStroke/VTE Quality Measure Build for Meaningful Use Stage 1
Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Presented by Susan Haviland, BSN RN Senior Consult, Santa Rosa Consulting Meaningful Use Quality Measures Centers for Medicare and Medicaid Services
More informationThe Efficacy of Continuous Bupivacaine Infiltration Following Anterior Cruciate Ligament Reconstruction
The Efficacy of Continuous Bupivacaine Infiltration Following Anterior Cruciate Ligament Reconstruction Heinz R. Hoenecke, Jr., M.D., Pamela A. Pulido, R.N., B.S.N., Beverly A. Morris, R.N., C.N.P., and
More information1 new lease on life. Zero hospital stay.
Information Line: 303-381-5404 1 new lease on life. Zero hospital stay. Total Joint Replacement Surgery in an Ambulatory Surgery Center reduces costs and risk of infection with excellent quality results.
More informationDISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION
DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION Venous thromboembolism is the most common complication after total hip and total knee arthroplasty. In recent times members of the Australian Orthopaedic
More informationCost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip
Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationOutpatient strategies in the management of deep
PRIMER: THE LOVELACE OUTPATIENT TREATMENT PROGRAM Alex C. Spyropoulos, MD Outpatient strategies in the management of deep venous thrombosis (DVT) are gaining acceptance in U.S. health care centers. Observational
More informationHow To Take Xarelto
A patient's guide Your clinic's contact details are: Name: Contact number: Contents 2 Why have I been prescribed Xarelto? 2 What is Xarelto? 3 How do I take Xarelto? 3 What should I do if I miss a dose
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report August 2015 Drug rivaroxaban (Xarelto) Indication Listing request Manufacturer Treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary
More informationWorkshop on Patient Support and Market Research Programmes
Workshop on Patient Support and Market Research Programmes Spectrum of programmes falling under the terms of PSP and MRPs and the and the type of safety data collected Pharmaceutical Industry Associations
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 General Principles: There is compelling data in the medical literature to support
More informationCLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014
CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 e 55 0495 2 Emergency Department (ED)- 1 Emergency Department Throughput Median time from
More informationUNILATERAL VS. BILATERAL FIRST RAY SURGERY: A PROSPECTIVE STUDY OF 186 CONSECUTIVE CASES COMPLICATIONS, PATIENT SATISFACTION, AND COST TO SOCIETY
UNILATERAL VS. BILATERAL FIRST RAY SURGERY: A PROSPECTIVE STUDY OF 186 CONSECUTIVE CASES COMPLICATIONS, PATIENT SATISFACTION, AND COST TO SOCIETY Robert Fridman DPM, Jarrett Cain DPM, Lowell Weil Jr. DPM,
More informationHow To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto
News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval
More informationRivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
DOI: 10.3310/hta13suppl3/07 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal M Stevenson,* A Scope, M Holmes,
More informationCDEC RECORD OF ADVICE
CDEC RECORD OF ADVICE RIVAROXABAN (Xarelto Bayer Inc.) Indication: Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism This document summarizes the Canadian Drug Expert Committee (CDEC) response
More informationRivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery
for preventing venous thromboembolism after hip or knee replacement surgery (riv-ah-rocks-ah-ban) Summary Rivaroxaban is an oral anticoagulant and the first direct factor Xa inhibitor. Rivaroxaban has
More informationEvidence Review. Topic: Same-day Mobilization following Total Hip and Total Knee Arthroplasty
Evidence Review Revised October 01, 2009 Topic: Same-day Mobilization following Total Hip and Total Knee Arthroplasty Background Hip and knee arthroplasty patients routinely receive postoperative physiotherapy
More informationPublished 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit
Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More information8/5/2015. Double Checking Practices. Background. Does a Double Checking Insulin Procedure Improve Patient Safety?
Disclosure to Participants Notice of Requirements For Successful Completion Please refer to learning goals and objectives Learners must attend the full activity and complete the evaluation in order to
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationPharmacological prophylaxis for venous thromboembolism
Pharmacological prophylaxis for venous thromboembolism Essence of this ArticleFor more than 20 years, routine preventive anticoagulant therapy has been the standard of care after major orthopaedic surgery.
More informationMN Community Measurement Total Knee Replacement Impact and Recommendation Document June 2010
MN Community Measurement Total Knee Replacement Impact and Recommendation Document June 2010 Degree of Impact Relevance to Consumers, Employers and Payers Annually there are over 500,000 total knee replacement
More informationGruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
More informationHow To Manage An Anticoagulant
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
More informationSeptember 12, 2011. Dear Dr. Corrigan:
September 12, 2011 Janet M. Corrigan, PhD, MBA President and Chief Executive Officer National Quality Forum 601 13th Street, NW Suite 500 North Washington, D.C. 20005 Re: Measure Applications Partnership
More informationImproving Appropriate Use of Proton Pump Inhibitors as Gastrointestinal Prophylaxis in the Hospital Setting
Improving Appropriate Use of Proton Pump Inhibitors as Gastrointestinal Prophylaxis in the Hospital Setting DATE Educating for Quality Improvement & Patient Safety 1 The Team Division CS&E Participants
More informationrivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC
rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationINFORMED CONSENT FOR SLEEVE GASTRECTOMY
INFORMED CONSENT FOR SLEEVE GASTRECTOMY This informed-consent document has been prepared to help inform you about your Sleeve Gastrectomy including the risks and benefits, as well as alternative treatments.
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infusion_therapy_in_the_home 3/1998 2/2016 2/2017 2/2016 Description of Procedure or Service Home infusion
More informationPractice Pearls in the Changing Face of Anticoagulant Therapy
Practice Pearls in the Changing Face of Anticoagulant Therapy A midday symposium about the use of anticoagulation to prevent venous thromboembolism (VTE) was held at and broadcast live from the 44th ASHP
More informationDr NG FU YUEN Associate Consultant Department of Orthopaedics and Traumatology Queen Mary Hospital
Dr NG FU YUEN Associate Consultant Department of Orthopaedics and Traumatology Queen Mary Hospital Aging Population in Hong Kong Life Expectancy Female 86 Male 81 Figure from Census and Statistics Department,
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More informationPreventing Readmissions
Emerging Topics in Healthcare Reform Preventing Readmissions Janssen Pharmaceuticals, Inc. Preventing Readmissions The Patient Protection and Affordable Care Act (ACA) contains several provisions intended
More informationOutpatient Anticoagulation Treatment Packet
Emergency / Pharmacy Services Outpatient Anticoagulation Treatment Packet Check when complete (If indicated): Primary Care Provider Follow Referral to Franciscan Transitional Clinic (if no primary care
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationMedicines reconciliation on admission and discharge from hospital policy April 2013. WHSCT medicines reconciliation policy 1
Medicines reconciliation on admission and discharge from hospital policy April 2013 WHSCT medicines reconciliation policy 1 Policy Title Policy Reference Number Medicines reconciliation on admission and
More informationPaul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, 1998-1999. A. Objective
A comparison of six months of anticoagulation with extended anticoagulation for a first episode of venous thromboembolism in patients with thrombophilia Paul G. Lee A. Objective a. To evaluate the risk
More informationEnoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications
More informationInsulin Therapy and Patient Choice - Study Update
Insulin study series: The Wessex Starting Insulin Study: practicalities of initiating insulin Jill Rodgers Article points The delivery system used for initiation of insulin therapy varied according to
More informationPartnership for Healthcare Payment Reform Total Knee Replacement Pilot Quality Report Quarter 1 Quarter 4, 2013
Partnership for Healthcare Payment Reform Total Knee Replacement Pilot Quality Report Quarter 1 Quarter 4, 2013 Introduction This report outlines the total knee replacement pilot quality results for care
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationExecutive Summary. Motive for the request for advice
Executive Summary Motive for the request for advice Currently nearly 400,000 people in the Netherlands are being treated with anticoagulants of a type Vitamin K antagonists (VKAs). Although VKAs are very
More informationI know my value. Be an active part of your anticoagulation therapy with INR self-monitoring
I know my value Be an active part of your anticoagulation therapy with INR self-monitoring INR* self-monitoring needs only a drop of blood, is easy, fast and decreases the possibility Be involved in your
More informationCartilage Repair Center
Cartilage Repair Center Tom Minas, MD, MS 850 Boylston Street, Suite 112 Andreas Gomoll, MD Chestnut Hill, MA 02467 Courtney VanArsdale, PA-C P: 617-732-9967 Lindsey Oneto, PA-C F: 617-732-9272 (Minas)
More informationAnti-Coagulation Therapies: A Review of Best Practices for Managing Risk
Volume 20 No. 1 Spring 2012 Anti-Coagulation Therapies: A Review of Best Practices for Managing Risk Dear Colleague: This first newsletter of 2012 deals with an important aspect of patient care the monitoring
More informationLow Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationUncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser
Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead
More informationReview Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty
Thrombosis Volume 2013, Article ID 762310, 5 pages http://dx.doi.org/10.1155/2013/762310 Review Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More informationPROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults
PROTOCOL NUMBER: 7 PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults THIS PROTOCOL APPLIES TO: UW Health Clinics: all adult outpatients with an active order for warfarin TARGET
More informationHot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
More informationChapter 15. Reconstitution and Dosages Measured in Units. Copyright 2012, 2007 Mosby, Inc., an affiliate of Elsevier Inc. All rights reserved.
Chapter 15 Reconstitution and Dosages Measured in Units 1 Objectives Calculating drug dosage problems that first require reconstitution of a powdered drug into a liquid form Using a proportion to solve
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More informationThe Impact of Regional Anesthesia on Perioperative Outcomes By Dr. David Nelson
The Impact of Regional Anesthesia on Perioperative Outcomes By Dr. David Nelson As a private practice anesthesiologist, I am often asked: What are the potential benefits of regional anesthesia (RA)? My
More informationDeborah Young, RN, BSN, CNOR Green Belt Charleston Area Medical Center
Deborah Young, RN, BSN, CNOR Green Belt Charleston Area Medical Center Charleston Area Medical Center Charleston, West Virginia 5,818 Employees 913 Licensed Beds 392 General Hospital 375 Memorial Hospital
More informationAntibiotic Prophylaxis for the Prevention of Infective Endocarditis and Prosthetic Joint Infections for Dentists
PRACTICE ADVISORY SERVICE FAQ 6 Crescent Road, Toronto, ON Canada M4W 1T1 T: 416.961.6555 F: 416.961.5814 Toll Free: 1.800.565.4591 www.rcdso.org Antibiotic Prophylaxis for the Prevention of Infective
More informationDr. Anseth s Frequently Asked Questions about Knee Replacement Surgery
Dr. Anseth s Frequently Asked Questions about Knee Replacement Surgery What hospital do you use? Abbott Northwestern Hospital What type of anesthesia do you use? General anesthesia with an additional nerve
More informationEvidence Review. New Oral Anticoagulants. Background. Search for non-cochrane reviews and RCTs.
Evidence Review Created on: October 01, 2009 Topic: New Oral Anticoagulants Background Elective total hip arthroplasty (THA) and total knee arthroplasty (TKA) are associated with a high risk of postoperative
More informationFor Technical Assistance with HCUP Products: Email: hcup@ahrq.gov. Phone: 1-866-290-HCUP
HCUP Projections 2003 to 2012 Report # 2012-03 Contact Information: Healthcare Cost and Utilization Project (HCUP) Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 http://www.hcup-us.ahrq.gov
More informationOral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
More information